Vanoglipel (INN), also known by its developmental code name DA-1241, is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.